A California-based biopharmaceutical company announced immunogenicity and safety results of the ongoing clinical trial evaluating HEPLISAV-B®, a Hepatitis B Vaccine (HVB) in patients undergoing hemodialysis.
Findings based on an online survey of more than 1,800 pregnant women
Food insecurity also tied to lower-quality diet in older adults
However, lower education, income, and perceived threat of COVID-19 tied to lower likelihood
Most common symptoms at six months were fatigue or muscle weakness, sleep difficulties, anxiety or depression
Rates at beginning and end of study and extent of change in rates significantly vary across states
China has stalled on admitting the independent group of WHO experts into the country
Company also looking to widen eligibility for the vaccine to include pregnant women, children, and others